NMRA-266 (M4 PAM)
Schizophrenia
PreclinicalIND-enabling
Key Facts
About Neumora Therapeutics
Neumora Therapeutics aims to transform the treatment of neuropsychiatric and neurodegenerative disorders by developing precision therapies based on biological subtypes. The company's platform integrates data science, neurobiology, and clinical development to match the right drug to the right patient. Its most advanced asset, navacaprant, represents a novel mechanism for depression, with a Phase 3 program underway. Backed by significant venture capital and a high-profile IPO, Neumora is positioned as a leader in the next generation of neuroscience drug development.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |